Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adc Therapeutics Sa
(NY:
ADCT
)
3.070
+0.250 (+8.87%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adc Therapeutics Sa
< Previous
1
2
3
4
5
6
7
8
Next >
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics - Time For A Turn-Around?
February 27, 2024
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors.
Via
Talk Markets
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
February 20, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Analyst Expectations for ADC Therapeutics's Future
November 20, 2023
Via
Benzinga
The Latest Analyst Ratings for ADC Therapeutics
September 12, 2023
Via
Benzinga
A Preview Of ADC Therapeutics's Earnings
August 07, 2023
Via
Benzinga
4 Analysts Have This to Say About ADC Therapeutics
July 25, 2023
Via
Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
February 08, 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via
InvestorPlace
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Provides Business Updates
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger...
Via
Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
October 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
July 21, 2023
On Friday, 54 companies hit new 52-week lows.
Via
Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
July 21, 2023
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...
Via
Benzinga
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.